INDEX

4-Hydroxynonenal, 180

A
Aberrant glycosylation, 77
Abruptio, 343
Acute coronary syndrome, 119
Acute kidney injury, 237, 262
Acute liver injury, 210
Adrenomedullin (ADM), 137
AIDS, 381
  rapid progression, 387
Airway, 159
  epithelial damage, 162
  fibrosis, 165
  inflammation, 164
Albumin, 174
Algorithmic models, 16
Alpha fetoprotein, 323
Alpha-1-acid glycoprotein, 286
ALT isoforms, 216
ALT isozymes, 214
ALT protein, 216
Alveolar apoptosis, 167
Alveolar epithelial cells, 161, 166
Alveolar macrophage, 161
Alveolar phospholipidosis, 169
Alzheimer’s, 91, 105, 109
  environmental exposures, 94
  Amyoacetion, 334
  Analytic strategies, 50
  Anatomy, vascular, 283
  Aneploidyic-trisomies, 323
  Aneuploidy screening, 334
  Angiogenic, 338
  Angiogenic proteins, 339
  Antibody-antigen reactions, 499
  Anorexia, 218
  Antibodies, 496
  monoclonal, 427, 449
  Antibody paratopes, 499
  Antibody-based tests, 39
  Antigen binding, 499
  Antigen-antibody reactions, 499
  Antigenic epitopes, 499
  Antigens, 426
  Apoptosis, 205
  Ascorbate, 178
  Ascorbic acid, 178
  Asthma, 164
  Asymmetric dimethyl arginine, 182
  ATP, 412

B
B lymphocytes, 496
B-type natriuretic peptide (BNP), 134

595
Bacteriophages, 512
Bead-based arrays, 440
Biliary injury, 219
Binding assays, 503
Bio-barcode assays, 459
Biochip array, 447
Biochip, manufacturing, 448
Biofluid proteomes, 32
Biofluids, 27
Bioinformatics, 13
Biological materials, 425
Biomarker dualification data submission, 585
Biomarker:
  performance metrics, 566
  pilot process, 585, 591
  qualification, 581
Biomarkers, 1, 16, 126, 138, 157, 209, 425, 457, 519, 536, 549, 561, 569, 581
development, 564
discovery, 56, 58
genomic, 582
methods to quantify, 108
prognostic, 577
regulatory perspective, 581
research, 425, 549, 561
sensitivity, 566
specificity, 566
types, 563
Biomonitoring, 523, 532
Blinded design, 553
Blood coagulation, 185
Blood urea nitrogen, 244, 564
Breast cancer, 357
Bronchitis, 164
Bronchoalveolar lavage fluid, 174, 176, 182
Bronchoalveolar lavage, 158, 171
Bronchoconstriction, 165
Bronchoscopy, 171

C
Calcium homeostasis, 208
Calprotectin, 286
Cancer antigen, 129, 365
Cancer, 59, 77, 355, 369, 592
biomarkers, 357
breast, 357
growth factors, 362
ovarian, 364
pancreatic, 367
prostate, 362
Cantilever, 470
Capillary endothelial, 166
Capillary endothelium, 162
Carinoembryonic antigen, 463
Cardiac disease, 127
Cardiac injury, 119
Cardiac stress, 134
Cardiomyopathy, 124
Cardiovascular disease, 61
Careful confirmatory data analysis, 562
Case control study, 550
Caveolin-1, 286
CCR2-64I, 385
CCR5, 284
CD4+, 389
CD40, 130
C-fibers, 161
Chemiluminescent immunoassays, 435, 505
Chemokine polymorphisms, 385
Chemokine receptors, 382
Chemokines, 177, 382, 392
Chlamydia trachomatis, 512
Cholestatic liver injury, 204
Chorionic villi sampling, 334
Chromatography, 50, 52, 225
Chronic disease, 310
Chronic kidney injury, 237
Chronic obstructive pulmonary disease (COPD), 165
CINC-1, 289
Circulating endothelial cells, 288
Clark electrode, 407
Clinical study, 549
Clinical trials, 18
  human, 575
Clusterin, 253
Cohort study, 550
Collagen, 184
Collisional induced disassociation (CID), 30
Colorimetry, 504
Complement component 3, 288
Compounds, 282
Computer tomography, 534
Confirmatory data analysis, 562
Congenital disorders, glycosylation (CDG), 75
Connective tissue growth factor, 288
Controlled trial, 551
Conventional assays, 441
Coronary artery disease, 123
Crabtree effect, 406
C-reactive protein (CRP), 127, 289, 592
Creatine kinase-myocardial band, 131
Cross sectional study, 549
Crossover, 553
Crystalline nephropathy, 239
Cumulative risk, 522, 532
Cytokines, 177
Cytoskeleton, 208

D
Data analysis, 12
Data interpretation, 13
Data management, 12
DEGs, 8
Developmental immunotoxicity, 313
Diabetes, gestational, 343
Diagnosis, 2, 10
Differential exposure, immunotoxicity, 314
Disease, 15, 58, 61, 79, 91, 554
prognostication, 556
Disease monitoring, 556
Dog, DIVI, 284
Dopaminergic cells, 96
Drug-induced, 281, 286, 292, 401
Dye-doped, 464

E
ECG, 119, 125
Ecitotoxicity, 97
Effector functions, 499
Elastin, 184
Electrochemiluminescence, 445
Electron transport system, 399
Emphysema, 167
Endogenous plasma, 427
Endoglin, 338
Endothelin-1, 289
Environmental chemical, 527
Environmental exposure, 519
Environmental health, 62, 525
Environmental risk, 520
biomarkers, 522
Enzyme immunoassay, 432
Enzyme-linked immunosorbent assay, 431
Epigenetic, 186
Estrogen receptor, 358
European medicines, 589
European Medicines Agency, 591
Exhaled nitric oxide, 181
Experimental studies, 551
Exploratory data analysis, 562
Expression markers, 251
Extracellular domain, 359
Extracellular matrix, 166
Extracellular superoxide dismutase, 179

F
F(2)-isoprostanes, 180
Fas, 129
Fatty liver, 204
FDA, 581
Ferritin, 180
Fetal growth, 335
Fibrinogen, 289
Field effect transistor, 473
FloDots, 464
Flow-through assays, 506
Ft1, 337
Fluorescence, 504
Fluorescence in situ hybridization, 534
Fluorescence polarization immunoassay, 434
Fluorescent immunoassays, 433
Fluorescent labeling, 81
Fluorochrome-dyed microspheres, 507
Fluorometry, 504
Free radicals, 207

G
Generalized immune activation, 390
Genes, 7
differently expressed, 8
Genomic biomarkers, 582
Genomics, 25
Gestational diabetes, 343
Giant magneto resistance, 458
Giant magnetoresistive, 478
Glomerular filtration, 240
Glutamyl transferase activity, 175
Glutathione, 179
Glutathione-S-transferases, 250
Glycans, 75, 84
therapeutics, 79
Glycome analysis, 80
Glycomics, 75, 84
cancer, 77
immune disorders, 76
Glycoproteins, 497
Glycosylation, 75
congenital disorders, 75
Glycosylation alterations, 78
Goblet cell hyperplasia, 162
Gonadotropin, 224
Granuloma, 167
GRO, 289
GST, 250

H
Haptenized detection probes, 512
Haptenized primers, 511
Haptoglobin, 289
Harmonization, 586
Heart failure, 125
Heart-type fatty acid binding protein (H-FABP), 134
Heavy chains, 497
Heme oxygenase-1, 181
Hemodynamic renal failure, 239
Hepatic regeneration markers, 222
Hepatic steatosis, 204
Hepatic toxicity, 402
Hepatocellular leakage enzymes, 221
Hepatocyte cell death, 205
Heterogeneous EIAs, 432
Heterogeneous enzyme immunoassay, 502
Heterogeneous fluorescent immunoassays, 433
Histopathology grades, 574
HIV, 381, 391
dementia, 388
genetic factors, 387
nephropathy, 387
non-opportunist, 387
viral load, 389
HLA alleles, 386
HLA, heterozygosity, 386
Homogenous enzyme immunoassays, 503
Homogenous fluorescent immunoassays, 433
Human chorionic gonadotropin, 224
Human vasculitides, 285
Hybridoma, 500
Hypercholesterolemia, 123
Hyper responsiveness, 165
Hypertension, 61

I
Identification, biomarkers, 3
Idiosyncratic, 203, 205, 410
Immune activation, generalized, 390
Immune disorders, glycomics, 76
Immune dysfunction, 310
Immune markers, 257
Immune system, 307
Immune biomarkers, 308, 312, 316
disease-based approach, 314
in vitro approach, 315
toxicogenomic, 315
Immunoassays, 425
chemiluminescent, 435, 505
enzyme-labeled antibody, 502
enzyme-labeled antigen, 502
fluorescent, 433
non-specific interactions, 506
Immunochromatography, 426
Immunodiagnostics, 495
Immunoglobulin A1 (IgA1), 77
Immunoglobulin supergene, 497
Immunohistochemistry, 83
Immunoradiometric assays, 430
Immunotoxicity, 307, 316
developmental, 313
differential exposure, 314
targets, 309
Induced sputum, 170
Infections, 310
Infectious disease, 61
Inhibin A, 325
Innovation task force, 590
Insulin resistance, 61
Interleukins, 129
Internal reflection fluorescence, 482
International Conference on
Harmonisation, 590
Interstitium, 162
Interventional studies, 557
Intrauterine growth restriction, 341
Intrinsic liver injury, 203
In vitro, mitochondrial dysfunction, 401
Iron-binding, 180
Ischemia, 123, 126
Isotope, 414
Isotopologues, 50

K
Kallikreins, 363
Kidney biomarkers, 244
Kidney injury, 237, 564
diagnosis, 242
Kidney project, 564
Kidney safety, 258

L
Labeling techniques, 81
Lactate dehydrogenase activity, 175
Lactic acidosis, 401
Lateral flow, 495, 507, 510, 513
Leakage markers, 250
Lectoferrin, 180
Leukocyte antigens, 386
Lewy bodies, 96
Light chains, 497
Light scattering, 468, 505
Likelihood ratio, 570
Lipid glycosylation, 79
Lipophilic persistent organic pollutants, 524
Liposome, 475
Liver fibrosis, 222
Liver injuries, inflammation markers, 220
Liver injury, 203, 226
biomarkers, 209
cholestatic, 205
drug-induced, 203
immune responses, 206
metabolic idiosyncrasy, 206
underlying inflammation, 207
Liver, cell membrane, 208
Luminescence, 505
Luminescent probes, 464
Luminex, 443
Lung biopsy, 171
Lung disease, environmental, 159
Lung injury, 158, 162, 171, 183
biomarkers, 172, 174
Lung, 157, 177
Lung-cell-specific proteins, 184

M
Macromolecules, 505
Magnetic resonance imaging, 534
Malate dehydrogenase, 212
MAQC, 10, 16
Mass spectrometry (MS), 26, 29, 35, 43, 50, 80, 224
Matrix metalloproteinase, 124, 130, 183, 361
Metabolic idiosyncrasy, 206
Metabolic profiles, 59, 62
Metabolic syndrome, 61, 218
Metabolites, 50, 63
Metallothionein-1, 290
Methods to quantify biomarkers, 108
Methylation, 186
Metabolic profiling, 47
Microarray, 8, 20, 82, 369, 445, 447
tissue, 37
Microfabrication, 457, 483
Mitochondria, 16, 207
Mitochondrial diseases, 411
Mitochondrial dysfunction, 401
animal models, 416
biomarkers, 413
drug-induced, 406
Mitochondrial oxidant stress, 207
Mitochondrial physiology, 403
Mitochondrial respiration, 407
Mitochondrial tomogram, 406
Mitochondrial toxicity, 402
Molecular classification, 10
Molecular epidemiology, 534
Monitoring fragment ions, 40
Monoclonal antibodies, 427, 449
Monocyte chemoattractant protein-1, 290
Mucus, 160
hypersecretion, 162
Multi-analyte, 441
Multimarker approach, 138
Multiple affinity removal system (MARS), 31
Multiple arm, 553
Multiplexing, 440
Myeloperoxidase, 131
Myocardial cell injury, 131
Myocardial infarction, 119

N
N-acetyl glucosaminidase activity, 176
Nanoelectromechanical, 470
Nanofluidics channels, 483
Nanomaterials, 482
Nanoparticles, 464, 501
Nanoscale, 457, 483
Nanostructures, 457

Nanotag, 480
Nanotubes, 473
Nanowires, 473
Necrosis, 205
Nephrotoxicity, 240
Nested case control study, 550
Neurodegenerative diseases, 91
Neurofibrillary tangles, 93
Neuroscience, 59
Neurotic plaques, 93
Neutrophil gelatinase-associated lipocalin, 290
Neutrophilic inflammation, 167
NMR spectroscopy, 50, 52, 62
Normalization, 53
Novel biomarkers, 102, 185, 244, 334, 382, 407, 581
N-terminal ProBNP, 134
Nucleic acid, 510

O
Observational studies, 553
Obstetric medicine, 323
One-antibody, 437
Optical detection, 459
Orosomucoid 1, 286
Osteoactivin, 255
Osteopontin, 255, 290
Ovarian cancer, 364
Overlapping critical data analysis, 562
Oxidative stress, 177, 205

P
Pancreatic adenocarcinoma, 367
Parallel two-arm, 553
Paraxonase, 212
Parkinson’s disease, 92, 107, 109
environmental factors, 97
markers, 101, 106
Partial hepatectomy study, 57
Particle capture, 506
Pathological discovery, 56
Pharmaceutical industry, 589
Placebo effect, 553
Placental growth factor, 336
Planar antibody arrays, 436
Planar protein array, 437
Plasma, 177, 182
  complement component 3, 288
  mass spectroscopy, 534
Plasma protein-A, 324
Plasma viral load, 389
Point-of-care diagnostics, 495
Polarographic, 407
Polyarteritis nodosa, 286
Polybrominated biphenyls, 534
Polybrominated diphenyl ethers,  
  524, 527, 531
Polyclonal antibodies, 500
Polycyclic aromatic hydrocarbons,  
  534
Polymorphisms
  chemokine, 385
  genes, 387, 391
Positron emission tomography, 534
Potentiometric dye, 405
Preclinical species, 285
Preeclampsia, 335, 338
  biomarkers, 340
Predictive Safety Testing
  Consortium, 214
Prefractionation strategy, 32
Pregnancy, 325, 342
Pre-processing, 54
Preterm labor, 342
Primate, DIVI, 285
Profile measurements, 55
Progesterone receptor (PR), 358
Prognosis, 10
Prognostic biomarkers, 577
Prostate cancer, 362
Prostate-specific antigen, 362
Protein, 174
Protein identification, 29
Proteomics, 25
Proviral DNA levels, 390
Pulmonary edema, 166
Pulmonary fibrosis, 167
Pulmonary surfactant, 169
Purine nucleoside phosphorylase,  
  212
Q
Qualification, 581
Qualification team, 593
Quantum dots, 461
R
Radioimmunoassay, 427
Radioisotopes, 429
Raman dyes, 466
Rapid immunoassays, 501
Rat, DIVI, 284
Reactive oxygen species, 219
Receiver-operator characteristic  
  curve, 567
Reference standard, 572
Regulatory path, 583
Regulatory perspective, 581
Respiratory bronchioles, 162
Risk assessment, systems biology,  
  539
Risk assessment, toxicity pathway- 
  based, 537
S
S100A9/A8, 286
Sample preparation, 30
Sandwich type assays, 430
SDF1-3’A, 385
Self-organising maps, 61
Separated confirmatory data  
  analysis, 562
Serum creatinine, 564
Serum cystatin C, 245
Serum enzyme biomarkers, 212
Serum proteins, 225
Sexually transmitted infections,  
  512
Single photon emission computed  
  tomography, 534
Smooth muscle actin, 291
Soluble labels, 502
Spontaneous lesions, 285
Sputum, 174, 177, 182
ST2, 138
Statistical confidence, 38
Statistical issues, 561, 576
Statistical methods, 8
Steatohepatitis, 204
Stokes' shifts, 505
Subtractive proteomics, 33
Surface enhanced Raman scattering, 460
Surface enhanced Raman spectroscopy, 467
Surfactant proteins, 182
Surfactant protein abnormalities, 169
Surrogate endpoint, 563
Suspension, 440
Symmetric dimethyl arginine, 182
Symptomatic change, 221
Systems approaches, 539

T
Target pathways, 56
T-cell depletion, 389
Technology, 8, 28, 258
Terminal bronchiolar injuries, 166
Therapeutics, glycans, 79, 84
Thrombosis, 185
Thrombospondin-1, 291
Time-resolved fluorescence, 505
Tissue inhibitor of metalloprotei-
nases-1, 291
Tissue microarray, 37
Tissue, 28, 36, 60, 208
Tissue plasminogen activator, 291
Toxicity, 15, 57
Toxicant-induced, 309
Toxicity pathway, 537
Toxicology, 56, 558
Toxiogenomic, 315
Transcriptomics, 26
Transferrin, 180
Treatment response, 557
Trefoil factors, 257
Trisomy 13, 327
Trisomy 18, 327
    prenatal, 332
Trisomy 21, 325
    prenatal, 328
Troponins, 132
Tubular reabsorption, 240
Tumor necrosis factor (TNF), 129
Tumors, 310

U
Un-blinded design, 553
Unconjugated estriol, 325
Uncontrolled trial, 551
Urinary albumin, 247
Urinary cystatin C, 249
Urinary interleukin 18, 257
Urinary Kim-1, 251
Urinary liver-type fatty acid-
    binding protein, 256
Urinary microglobulin, 248
Urinary NAG, 251
Urinary total protein, 246
Urinary trefoil factor 3, 257
Urokinase plasminogen activator,
    359

V
Vascular anatomy, 283
Vascular cell adhesion molecule 1,
    291
Vascular endothelial growth factor,
    292, 335
    receptors, 336
Vascular injury, 281
    biomarkers, 287
VEGFR1, 337
Villi sampling, 334
Von Willebrand factor, 292

W
Warburg effect, 59, 406

X
Xenobiotics, 205